Praxis Precision Medicines Inc (PRAX)

08:49 AM

What analysts say about Praxis Precision Medicines Inc. stock outlookFree Market Volatility Navigation Tips - jammulinksnews.com

08:49 AM

05:28 AM

Why Praxis Precision Medicines Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser

05:28 AM

02:58 AM

Will Praxis Precision Medicines Inc. stock benefit from AI tech trendsPhenomenal capital gains - jammulinksnews.com

02:58 AM

12:59 PM

Praxis Precision Medicines Inc. Stock Analysis and ForecastTremendous return on equity - Autocar Professional

12:59 PM

Jul 24, 2025

Is Praxis Precision Medicines Inc. a good long term investmentExceptional profit potential - PrintWeekIndia

Jul 24, 2025

Jul 23, 2025

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jul 23, 2025

Jul 23, 2025

What analysts say about Praxis Precision Medicines Inc. stockBreakthrough capital growth - jammulinksnews.com

Jul 23, 2025

Jul 23, 2025

What drives Praxis Precision Medicines Inc. stock priceConsistent triple-digit returns - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

Major Depressive Disorder Clinical Trials, Companies, - openPR.com

Jul 22, 2025

Jul 22, 2025

What makes Praxis Precision Medicines Inc. stock price move sharplyFree Stock Selection - Newser

Jul 22, 2025

Jul 22, 2025

Does Praxis Precision Medicines Inc. stock pay reliable dividendsShort Squeeze Radar - Newser

Jul 22, 2025

Jul 21, 2025

Praxis Precision Medicines’ (PRAX) Buy Rating Reiterated at HC Wainwright - Defense World

Jul 21, 2025

Jul 20, 2025

(PRAX) Trading Report - news.stocktradersdaily.com

Jul 20, 2025

Jul 19, 2025

Here's Why We're Not Too Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Situation - 富途牛牛

Jul 19, 2025

Jul 18, 2025

Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy - Investing.com Nigeria

Jul 18, 2025

Jul 18, 2025

Praxis Precision Medicines stock gets BTD for relutrigine, H.C. Wainwright maintains Buy By Investing.com - Investing.com South Africa

Jul 18, 2025

Jul 18, 2025

PRAX: HC Wainwright & Co. Reiterates Buy Rating with $105 Target - GuruFocus

Jul 18, 2025

Jul 17, 2025

Praxis Precision gets FDA breakthrough therapy status for Relutrigine - Seeking Alpha

Jul 17, 2025

Jul 17, 2025

FDA grants breakthrough therapy designation to Praxis’ relutrigine for pediatric epilepsy - Investing.com Canada

Jul 17, 2025

Jul 17, 2025

Q1 Earnings Forecast for PRAX Issued By HC Wainwright - Defense World

Jul 17, 2025

Jul 17, 2025

Praxis Precision Medicines and the Breakthrough Potential of Relutrigine in Rare Epilepsy Therapies: Strategic and Financial Implications of FDA Breakthrough Therapy Designation - AInvest

Jul 17, 2025

Jul 17, 2025

Praxis Says FDA Grants Breakthrough Therapy Designation To Relutrigine For Rare Pediatric Epilepsies - Nasdaq

Jul 17, 2025

Jul 17, 2025

FDA grants breakthrough therapy status to Praxis’s relutrigine By Investing.com - Investing.com Canada

Jul 17, 2025

Jul 17, 2025

FDA grants breakthrough therapy status to Praxis’s relutrigine - Investing.com Australia

Jul 17, 2025

Jul 17, 2025

Praxis Precision Medicines Gains FDA Breakthrough Designation - TipRanks

Jul 17, 2025